It’s all in the protocol. Anatomic is inspired by human development. We utilize serum-free, chemically defined media formulations, recombinant or synthetic matrices, and small molecules/ recombinant growth factors to drive de-novo differentiation of pure neuronal subpopulations. These protocols developed with high-quality inputs eliminate variability seen when using undefined reagents.
These high-efficiency protocols are possible because of Anatomic’s scientific breakthrough in discovering conditions to manufacture Primal Ectoderm within a mere 24 hours. This naive ectodermal population is maximally flexible, and provides near-instantaneous access to difficult-to-engineer patterning stages important for generating neuronal diversity. A “shortcut-to-shortcuts”, this platform technology results in a drastically accelerated differentiation trajectory which enables the manufacture of immature neurons within only one week.
Anatomic's specialty media allows neuroscience researchers to drastically accelerate manufacture of neurons from human pluripotent stem cells.
Founded by University of Minnesota stem cell researchers developing a treatment for spinal cord injury, Anatomic was born when these researchers stumbled upon an unrelated, but incredible discovery. Manufacturing neural tissue from stem cells is a prolonged, multi-month process standing in the way of revolutionizing human health. The founders of Anatomic developed a simple method to drastically accelerate this process, potentially throwing the doors open to the creation of new drugs for neurological disease.
Anatomic was created to commercialize this groundbreaking new technology by serving the drug discovery industry and basic researchers interested in understanding and treating neurological disease. Anatomic manufactures and provides highly consistent, genuine human neural tissues to these firms to accelerate their research into diseases such as Alzheimer’s, Parkinson’s, and chronic pain.
For more information about the scientific basis of Anatomic technologies, read our breakthrough publication.